Drug Type Small molecule drug |
Synonyms AMPAlex, 1-BCP, Ampakine CX 516 + [4] |
Target |
Mechanism AMPA receptor modulators(Glutamate receptor ionotropic AMPA modulators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC14H15N3O |
InChIKeyANDGGVOPIJEHOF-UHFFFAOYSA-N |
CAS Registry154235-83-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 3 | US | 01 Feb 2002 | |
Autistic Disorder | Phase 2 | US | 01 Jun 2002 | |
Fragile X Syndrome | Phase 2 | US | 01 Jun 2002 | |
Mild cognitive disorder | Phase 2 | US | 01 Apr 2002 |
Phase 2 | 175 | (CX516) | dahagdyoxt(jvazynjzyf) = yzsuoczggw glzkvdvscr (zujsiwdztu, iphgstddrt - uflthcicua) View more | - | 23 Jul 2018 | ||
Placebo (Placebo) | dahagdyoxt(jvazynjzyf) = zuubztpefc glzkvdvscr (zujsiwdztu, jhawmuduej - xawgxdysxe) View more |